Analysis of clinically actionable alterations in baseline tumor versus plasma samples in participants of the TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer - Pelzer, U; Oh, D-Y; Qin, S; Antonuzzo, L; Tougeron, D; Lee, C-K; Tan, B; Ikeda, M; Wang, J; Lin, H-Y; Lee, Y; McCoon, P; Valle, J W (Zeitschrift für Gastroenterologie, 2025)